Protein Engineering Design and Selection · 2012 · 37 citations · 29 references
PharmacyBiotechnologyMolecular BiologyAntibody EngineeringProtein EngineeringStructural BiologyAntibody DiscoveryAntibody FunctionAntibody StructureAntibody-antigen RecognitionBispecific AntibodiesLigand BindingBispecific Antibody ConjugatesBispecific Antibody DiscoveryBispecific Antibody FragmentsBispecific Antibody Specificity DesignCleavageDisulfide Bond StabilityDisulfide Bond StructureIgg-like Bispecific Antibodies
We have designed bispecific antibodies that bind one target (anti-Her3) in a bivalent IgG-like manner and contain one additional binding entity (anti-cMet) composed of one V(H) and one V(L) domain connected by a disulfide bond. The molecules are assembled by fusing a V(H,Cys44) domain via flexible connector peptides to the C-terminus of one H-chain (heavy chain), and a V(L,Cys100) to another H-chain. To ensure heterodimerization during expression in mammalian cells, we introduced complementary knobs-into-holes mutations into the different H-chains. The IgG-shaped trivalent molecules carry as third binding entity one disulfide-stabilized Fv (dsFv) without a linker between V(H) and V(L). Tethering the V(H) and V(L) domains at the C-terminus of the C(H)3 domain decreases the on-rates of the dsFv to target antigens without affecting off-rates. Steric hindrance resolves upon removal of one side of the double connection by proteolysis: this improves flexibility and accessibility of the dsFv and fully restores antigen access and affinity. This technology has multiple applications: (i) in cases where single-chain linkers are not desired, dsFvs without linkers can be generated by addition of furin site(s) in the connector that are processed during expression within mammalian cells; (ii) highly active (toxic) entities which affect expression can be produced as inactive dsFvs and subsequently be activated (e.g. via PreScission cleavage) during purification; (iii) entities can be generated which are targeted by the unrestricted binding entity and can be activated by proteases in target tissues. For example, Her3-binding molecules containing linkers with recognition sequences for matrix metalloproteases or urokinase, whose inactivated cMet binding site is activated by proteolytic processing.
29
Gene expression profiling predicts clinical outcome of breast cancer
Laura van ‘t Veer, Hongyue Dai, Marc J. van de Vijver et al. · Nature · 2002 · 9.6K citations · Full text
Genes that mediate breast cancer metastasis to lung
Andy J. Minn, Gaorav P. Gupta, Peter M. Siegel et al. · Nature · 2005 · 3K citations · Full text
Metastatic potential correlates with enzymatic degradation of basement membrane collagen
Lance A. Liotta, Karl Tryggvason, Spiridione Garbisa et al. · Nature · 1980 · 1.8K citations
An efficient route to human bispecific IgG
A. Margaret Merchant, Zhenping Zhu, Jean Q. Yuan et al. · Nature Biotechnology · 1998 · 509 citations